ClinicalTrials.gg
RecruitingNCT07245446Updated Nov 24, 2025

A Study of Ivonescimab in First-Line ES-SCLC

A Phase 2 interventional study of Ivonescimab and Cadonilimab in Extensive-stage Small Cell Lung Cancer (ES-SCLC), sponsored by Akeso. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
94th of 333
180 · median 63
Started
2025
with 59 others
Phase 2
153 of 365
70 open now
Primary completion
2027-12
later than 133 of 214 live
Registered
312th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 94th largest by planned enrollment of the 333 interventional ones that give a count, is one of 60 that started in 2025, is one of 153 in phase 2, reaches primary completion later than 133 of the 214 other live ones, and was the 312th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

The main questions the study aims to answer are:

  • What side effects do participants experience from these combination treatments?
  • How well do the treatments work to shrink tumors?

Researchers will compare three groups to see which combination works best. All participants will receive Ivonescimab and chemotherapy (etoposide and carboplatin). The differences are:

  • Group 1 will also receive an additional drug called AK117.
  • Group 2 will also receive a different additional drug called Cadonilimab.
  • Group 3 will receive Ivonescimab and chemotherapy only.

Participants will:

  • Be assigned by chance to one of the three groups.
  • Undergo an initial treatment phase (about 3 months), receiving chemotherapy plus the specific study drugs for their group.
  • If the treatment is effective and side effects are manageable, continue with a maintenance phase using only the study drugs (without chemotherapy) for up to 2 years.
  • Attend regular clinic visits for check-ups, blood tests, and imaging scans (like CT scans) to see how they are responding to the treatment.
03

Conditions studied

  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • No prior systemic therapy for ES-SCLC.
  • At least one as defined by v1.1.
  • Age 18 to 75 years.
  • (ECOG) performance status of 0 or 1.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Active or untreated central nervous system (CNS) (Treated, stable are allowed).
  • History of severe to monoclonal antibodies.
  • Active disease requiring systemic treatment within the past 2 years.
  • Significant cardiovascular disease.
  • Active or C, or infection.
  • Interstitial lung disease or non-infectious pneumonitis.
  • Significant bleeding tendency or risk, including tumor invasion of major blood vessels.
  • Pregnancy or lactation.
  • Other active within 5 years prior to enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Ivonescimab + AK117 + Chemotherapy

    Drug: Ivonescimab · Drug: AK117 · Drug: Etoposide · Drug: Carboplatin (AUC 5)

  • Experimental
    Ivonescimab + Cadonilimab + Chemotherapy

    Drug: Ivonescimab · Drug: Cadonilimab · Drug: Etoposide · Drug: Carboplatin (AUC 5)

  • Experimental
    Ivonescimab + Chemotherapy

    Drug: Ivonescimab · Drug: Etoposide · Drug: Carboplatin (AUC 5)

Interventions

  • Administered intravenously at a specified dose and frequency.

  • Administered intravenously at a specified dose and frequency.

  • DrugAK117

    Administered intravenously at a specified dose and frequency.

  • Administered intravenously at 100 mg/m² on Days 1-3 of each 3-week cycle for 4 cycles.

  • Administered intravenously at AUC 5 on Day 1 of each 3-week cycle for 4 cycles.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The proportion of participants achieving a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Up to approximately 2 years.

  2. Incidence of Adverse Events (AEs)

    The number and percentage of participants experiencing any Adverse Event (AE). An AE is defined as any untoward medical occurrence in a participant administered a study drug, which may not have a causal relationship with the treatment. Severity will be graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Time frame: From first dose up to 90 days after last dose.

Secondary outcomes

  1. Disease Control Rate (DCR)

    The proportion of participants achieving a BOR of CR, PR, or Stable Disease (SD), as assessed by the investigator per RECIST v1.1.

    Time frame: Up to approximately 2 years.

  2. Duration of Response (DoR)

    For responders (participants achieving CR or PR), DoR is defined as the time from the first documented evidence of CR or PR until the first documented disease progression or death from any cause, whichever occurs first, per RECIST v1.1.

    Time frame: Up to approximately 2 years.

  3. Time to Response (TTR)

    For responders (participants achieving CR or PR), TTR is defined as the time from the start of study treatment to the first documented objective response (CR or PR), per RECIST v1.1.

    Time frame: Up to approximately 2 years.

  4. Progression-Free Survival (PFS)

    PFS is defined as the time from the start of study treatment to the first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: Up to approximately 2 years.

  5. Overall Survival (OS)

    OS is defined as the time from the start of study treatment to death from any cause.

    Time frame: Up to approximately 5 years.

  6. Serum concentrations of Ivonescimab, Cadonilimab, and AK117

    Serum concentrations of Ivonescimab, Cadonilimab, and AK117 will be measured to characterize the pharmacokinetic (PK) profiles.

    Time frame: Up to approximately 2 years.

  7. Incidence of Anti-drug Antibodies (ADA)

    The immunogenicity will be assessed by the incidence of participants who develop detectable anti-drug antibodies (ADA) against Ivonescimab, Cadonilimab, and/or AK117.

    Time frame: Up to approximately 2 years.

07

Study locations

2 of 3 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100020, China
    Not yet recruiting
    • Zhijie Wang, MD, PhD · Contactwangzj@cicams.ac.cn · +86-10-87788525
    • Zhijie Wang, MD, PhD · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710000, China
    Recruiting
    • Yu Yao, MD, PhD · Contact13572101611@163.com · +86-13572101611
    • Yu Yao, MD, PhD · Principal investigator
  • Shanghai Pulmonary Hospital Affiliated to Tongji University
    Shanghai, Shanghai Municipality 200433, China
    Recruiting
    • Shengxiang Ren, MD, PhD · Contactharry_ren@126.com · +86-21-65102117
    • Shengxiang Ren, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's planned 26 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Nov 24, 2025
StartActual
Oct 29, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07245446
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Oct 29, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 24, 2025

Study contacts

Wenting Li
Contact
wenting01.li@akesobio.com
+86-18116403289

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion